Current AD treatments, which have also been used or tested in patients with CAA, DS and FTD [160,161,162,163], focuses on the inhibition of acetylcholinesterase enzyme (the ChEI drugs donepezil, rivastigmine and galantamine) and blocking the glutamate receptor NMDA (memantine). The gene discussed is ACHE; the disease is Dravet syndrome.